VIIV HEALTHCARE 209639(EMBRACE)
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Location | Midway Specialty Care Center West Palm Beach
VIIV HEALTHCARE 221611 (CROWN)
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Location | Midway Specialty Care Center West Palm Beach
GSK 219231
(B-FOCUS)
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection
Location | Midway Specialty Care Center West Palm Beach
INDIANA UNIVERSITY HCRN00
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in People Living with Human Immunodeficiency Virus (HIV)
Locations | Midway Specialty Care Center, West Palm Beach, and Midway Specialty Care Center, Fort Pierce
MIDWAY SPECIALTY CARE CENTER - INNOVATE STUDY
Real World Clinical Outcomes in PREP Cisgender Female Patients Who Start on Long Acting Cabotegravir: An Observational, Multisite Prospective 2 Year Study in the Southern U.S.
Location | Midway Specialty Care Center Orlando & West Palm Beach
VIIV HEALTHCARE 222638 (INNOVATE)
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of 2-drug Injectable Regimens of VH4524184 Plus Rilpivirine and of oral VH4524184 Plus DESCOVY in Treatment Naive Viremic Adults Living with HIV-1
Location | Midway Specialty Care Center, West Palm Beach
CO-US-380-7672 (REINITIATE)
Gilead CO-US-380-7672 – A multi-center, single-arm, open-label, prospective, Phase 4 study to investigate the safety and efficacy of rapidly restarting oral bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in viremic and virologically-suppressed male and female HIV-positive patients aged ≥18 years who are treatment-experienced and returning to care after experiencing a treatment interruption of ≥12 weeks
VIIV HEALTHCARE 222794 (CUATRO)
Study Evaluating the Efficacy, Safety and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting administered every 4 months in adults and adolescents living with HIV who are Virologically Suppressed on ART (CUATRO)
Location | Midway Specialty Care Center, West Palm Beach